Astrazeneca Lp v. Breath Limited
542 F. App'x 971
Fed. Cir.2013Background
- AstraZeneca appeals district court judgment that ’834 Patent claims are noninfringed and that ’603 Patent claims are invalid, and seeks remand due to claim construction.
- The ’834 Patent covers sterile budesonide as a micronized powder or suspension meeting USP sterility; claims 1 and 50 are the primary disputed ones.
- The ’603 Patent covers once-daily nebulized budesonide treatment for pediatric respiratory disease; only independent claim 1 is asserted.
- Appellees are generic defendants who filed ANDAs; AstraZeneca obtained a preliminary injunction against Apotex with a bond.
- The district court found no infringement for several ’834 claims, and invalidity for the asserted ’603 claims on obviousness/anticipation, while dismissing some Apotex counterclaims.
- The Third Circuit reverses on the ’834 claim construction (remanding for proceedings), affirms the obviousness ruling on the ’603 Patent, and affirms bond/other rulings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether 'micronized powder composition' imports a sterilization limitation | AstraZeneca: plain meaning does not require heat sterilization; no disavowal. | Appellees: specification/prosecution history limit the term to heat-sterilized forms. | Term without sterilization limitation; remand for new construction. |
| Whether the asserted claims of the ’603 Patent are obvious over prior art | AstraZeneca argues lack of motivation/expectation to combine references; not obvious. | Appellees contend the prior art teaches once-daily budesonide and nebulizer delivery; it was obvious. | We affirm the district court's obviousness finding. |
| Whether Apotex had proper jurisdiction to challenge invalidity of dismissed claims | Apotex seeks relief from invalidity for broader claims after noninfringement. | District court properly declined jurisdiction; no added benefit from invalidity ruling. | Court declines to review the district court's dismissal of invalidity as to dismissed claims. |
| Whether the district court erred in setting or modifying the injunction bond amount | Apotex seeks retroactive increase to cover past damages; argues Sprint safeguards apply. | AstraZeneca argues retroactive increases are improper and would misstate exposure. | Affirms district court's bond ruling; retroactive increase not warranted. |
Key Cases Cited
- Thorner v. Sony Computer Entm’t Am. LLC, 669 F.3d 1362 (Fed. Cir. 2012) (plain-meaning rule and disavowal standards for claim construction)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (obviousness analysis and teaching-aid inferences)
- Graham v. John Deere Co. of Kan. City, 383 U.S. 1 (U.S. 1966) (fundamental obviousness framework)
- Vanguard Prods. Corp. v. Parker Hannifin Corp., 234 F.3d 1370 (Fed. Cir. 2000) (product claims not limited by method of manufacture absent clear disclosure)
- Baldwin Graphic Sys., Inc. v. Siebert, Inc., 512 F.3d 1338 (Fed. Cir. 2008) (avoid reading process limitations into apparatus claims)
- Int’l Game Tech. v. WMS Gaming, Inc., 217 F.3d 850 (Fed. Cir. 2000) (procedural issues; standard of review for bond matters)
- Sprint Commc’ns Co. L.P. v. CAT Commc’ns Int’l, Inc., 335 F.3d 235 (3d Cir. 2003) (retroactive bond increases and injunctive exposure principles)
- Capo, Inc. v. Dioptics Med. Prods., Inc., 387 F.3d 1352 (Fed. Cir. 2004) (declaratory-judgment dismissal standards and discretion)
- Liquid Dynamics Corp. v. Vaughan Co., Inc., 355 F.3d 1361 (Fed. Cir. 2004) (discretion in mootness/invalidity counterclaims post-noninfringement)
- Nystrom v. TREX Co., Inc., 339 F.3d 1347 (Fed. Cir. 2003) (discretion to dismiss invalidity counterclaims when no infringement)
- Phonometrics, Inc. v. N. Telecom Inc., 133 F.3d 1459 (Fed. Cir. 1998) (discretion to dismiss invalidity as moot where no infringement)
- Ormco Corp. v. Align Tech., Inc., 498 F.3d 1307 (Fed. Cir. 2007) (broader vs. narrower claim validity considerations)